title: Chemical synovectomy with sodium morrhuate in the treatment of symptomatic recurrent knee joint effusion.
abstract: The aim of this study was to assess the efficacy and safety of intra-articular sodium morrhuate injections in the treatment of recurrent knee joint effusions. Ninety-eight knees of 92 patients (f = 59, m = 33) with knee arthritis of heterogeneous etiology were treated with chemical synovectomy (CSO). Of those, 39 patients suffered from rheumatoid arthritis (RA). The mean follow-up was 29.8 months. Clinical outcome was evaluated by analyzing subjective patient satisfaction, activity level, pain severity on the basis of the Visual Analogue Pain Scale (VAS), Lysholm and Gillquist score, and the Knee Injury and Osteoarthritis Outcome Score (KOOS). Fifty-seven percent of all patients and 67% of patients diagnosed with RA were satisfied with CSO. No significant effects on patient satisfaction by CSO were noted in patients older than 40 years. Overall, VAS, Lysholm and Gillquist score, and KOOS improved significantly at final review. The intra-articular application of sodium morrhuate is an effective and safe measure in the treatment of recurrent symptomatic knee joint effusions in young patients suffering from recurrent knee joint effusions.
authors.affiliation: Department of Orthopedic Surgery, University of Regensburg, Asklepios Klinikum Bad Abbach, Kaiser Karl V Allee 3, 93077 Bad Abbach, Regensburg, Germany.
authors.forename: Jens
authors.initials: J
authors.lastname: Schaumburger
authors.forename: Stefanie
authors.initials: S
authors.lastname: Trum
authors.forename: Sven
authors.initials: S
authors.lastname: Anders
authors.forename: Johannes
authors.initials: J
authors.lastname: Beckmann
authors.forename: Sebastian
authors.initials: S
authors.lastname: Winkler
authors.forename: Hans-Robert
authors.initials: HR
authors.lastname: Springorum
authors.forename: Joachim
authors.initials: J
authors.lastname: Grifka
authors.forename: Philipp
authors.initials: P
authors.lastname: Lechler
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018771:Arthralgia / Q000209:etiology / Q000517:prevention & control; D001168:Arthritis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D007270:Injections, Intra-Articular; D007719:Knee Joint / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D017060:Patient Satisfaction; D020127:Recovery of Function; D012008:Recurrence; D012189:Retrospective Studies; D012976:Sodium Morrhuate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D013583:Synovial Membrane / Q000187:drug effects* / Q000473:pathology; D013585:Synovitis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D012976:Sodium Morrhuate